Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and efficacy extension study of fremanezumab for cluster headache
NL-OMON49442Phase 3Active, not recruiting
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Apr 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, double-blind trial of fremanezumab in Cluster Headache (CH) (4 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoints: Occurrence of adverse events throughout the study, Change from baseline in clinical laboratory test results and 7 more. Started Apr 2018; status: active, not recruiting.
02
Drugs
fremanezumab
03
Conditions
Cluster Headache (CH)
Beyond the preview
Go deeper on NL-OMON49442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49442.